Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Cancer Prevention
•
Breast Cancer, Non-metastatic
•
Primary Care
How do you counsel patients about hormonal contraception in patients with high risk benign breast pathology (i.e. LCIS, ADH, ALH) who would quality for chemoprevention?
Related Questions
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
What is your preferred method of surveillance after mastectomy?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you offer neoadjuvant pembrolizumab to a TNBC patient with multiple pulmonary nodules and bilateral hilar adenopathy secondary to asymptomatic sarcoidosis (biopsy proven)?
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?
What are your top takeaways in Breast Cancer from ASTRO 2024?
